Treating advanced melanoma with immune checkpoint inhibitors (ICIs) can be safe and effective in patients with concomitant chronic lymphocytic leukemia (CLL), according to a study published in Annals of Oncology.
2023
Immunotherapy Combinations and Monotherapy Considered in a Patient With Metastatic Melanoma
During a Targeted Oncology™ Case-Based Roundtable™ event, Sajeve S. Thomas, MD, discussed key trials of immunotherapy in terms of safety and efficacy for patients with metastatic melanoma.
Opdivo, Opdualag Still Benefits Patients With Melanoma at 2 Years
After two years of follow-up, patients with advanced melanoma treated with Opdivo and Opdualag continued to obtain a survival benefit compared with Opdivo alone.
Novel Immune Checkpoint Inhibitors, Bispecific Antibodies Become Clinical Mainstays in Melanoma Nursing
What are the implications of new approvals for oncology nurses specializing in melanoma?